Objectives: To investigate the quality of life (QoL) in acromegalic patients in relation to biochemical parameters. Design and methods: Single-center, open label study in 14 acromegalic patients (eight woman and six men, age 33 -77 years), with normal serum IGF-I levels during long-term treatment with monthly injections of 20 mg of long-acting octreotide. We investigated which biochemical parameter might reflect optimal QoL, using the SF-36 questionnaire.

Long-term replacement therapy with rhGH in patients with adult-onset GHD induces a significant increase in Hb concentrations, while serum leucocyte and platelet counts do not change.